Status:
COMPLETED
Study Evaluating The Potential Effect Of Multiple Doses Of Neratinib On The Pharmacokinetics Of A Single Dose Of Digoxin
Lead Sponsor:
Puma Biotechnology, Inc.
Conditions:
Healthy
Eligibility:
All Genders
18-50 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate the potential effect of multiple doses of neratinib on the pharmacokinetics (how the body absorbs, distributes, metabolizes and/or excretes) of a single dose o...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Healthy men and women of non-childbearing potential, age 18-50
Exclusion
Key Trial Info
Start Date :
April 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2009
Estimated Enrollment :
27 Patients enrolled
Trial Details
Trial ID
NCT00860223
Start Date
April 1 2009
End Date
April 1 2009
Last Update
May 14 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Miami, Florida, United States, 33126